Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis

摘要: BACKGROUND: Long-term data of etanercept drug survival in patients with psoriasis daily practice are scarce. OBJECTIVES: The primary objective was to describe for a long-term cohort psoriasis. secondary identify determinants general and separately discontinuation due adverse events or ineffectiveness therapy. METHODS: Data were extracted from prospective treated biologics Drug analysed by Kaplan-Meier curves split two reasons discontinuation: ineffectiveness. Determinants using univariate Cox regression analysis multivariate backward selection. RESULTS: We included 193 (512 patient-years treated) maximum treatment duration 7.5 years. overall rates 77%, 41% 30% after 1, 4 years, respectively. mean 3.8 years (95% confidence interval 3.4-4.3). Reasons (33.7%), (11.9%), both (4.7%) other (e.g. pregnancy planned) (5.7%). related longer male sex [hazard ratio (HR) 0.55], prior anti-tumour necrosis factor (TNF)-alpha use (HR 0.57) lower dose 0.65). Younger age 0.83), body mass index 0.63) 0.71) decreased risk side-effects. A weekly CONCLUSIONS: present the longest date. sex, anti-TNF therapy dose. depended on reason etanercept.